Vistin Pharma Asa · OSL:VISTN
Vistin Pharma Asa — Investor Day (June 2023)
25 slides from Vistin Pharma Asa's investor day presentation, Jun 14, 2023
Slide 1: Vistin Pharma Capital Markets Day
sa Vistin Pharma Capital Markets Day
Slide 2: Agenda
Agenda - Vistin history and long-term strategy - Vistin metformin business - The Fikkjebakke plant; Operations and strategy - Plant Tour
Slide 3: Vistin – A leading global, fully integrated supplier of metformin
Vistin – A leading global, fully integrated supplier of metformin
Slide 4: Metformin products, manufacturing capacity and positioning
Producer of two Manufacturing Positioned as Strategically different metformin capacity a premium producer positioned with products in a competitive proximity to market key customers • Metformin HCl • Decided in April ‘20 to • Sales to reputable • Delivery time less (bulk API, “fine, dry invest MNOK
Slide 5: Long and successful growth track record
Long and successful growth track record Revenues Vistin Metformin (MNOK) Sales volume (MT) 350 4000 3748 305 3483 300 3500 3360 279 254 2932 2992 3000 250 2759 228 2511 2456 2481 2501 2500 201 2244 2316 200 176 171 177 2000 150 150 142 111 1500 101 100 88 1045 1000 50 500 0 0
Slide 6: Experienced management team
Experienced management team Name Role Experience • Previous experience includes several years in top management positions at Alpharma, Chief Executive a leading international generic pharmaceutical company Kjell-Erik Nordby Officer • Holds a Master's degree in Pharmacy and Master's degree in Busines
Slide 7: Strategic intent: Metformin leadership
Strategic intent: Optimize and grow our current business, strengthen our premium metformin supplier position… Metformin leadership • Build a >7000 metformin business through world class operations and strategic customer partnerships • Make Fikkjebakke the most technology advanced and environmentally
Slide 8: …and plan for the next wave of growth
Strategic intent: …and plan for the next wave of growth 2nd wave of growth • Build a multi product API European Contract Development and Manufacturing business(API CDMO) • A strong high margin API focus where the company is a leading player • Supplier of “short travelled” European APIs to internatio
Slide 9: CDMO market is divided by drug product development stage
CDMO market is divided into 4 activities according to drug product development stage – API production and FDF as main segments
Slide 10: 2019 CDMO global market reaches ~EUR 100 bn
2019 CDMO global market reaches ~EUR 100 bn with API manufacturing accounting for the largest market share (~60%)
Slide 11: Vistin metformin business
Vistin metformin business
Slide 12: Metformin is the 1st-line treatment for type 2 diabetes
Metformin is the 1st-line treatment for type 2 diabetes, being cost-efficient with limited side effects An estimated 537 million adults aged 20–79 years are currently living with diabetes. This represents 10.5% of the world’s population Today Vistin contribute to deliver Metformin diabetes type 2 me
Slide 13: Total number of diabetes patients expected to rise to 783 million by 2045
Total number of diabetes patients expected to rise to 783 million by 2045 (+46%) Number of people living with diabetes / Source: International Diabetes Federation, IDF Diabetes Atlas, tenth edition, 2021
Slide 14: Global metformin demand expected to grow to 67,000MT by 2028
Global metformin demand expected to grow by approximately 16.000MT to 67.000MT by 2028 Global sales development by product (MT) 2015 - 2028 QT Research / JC Market Research 80000 • Steady 4-6% annual CAGR growth 70000 • Asia Pacific (APAC) is the 60000 leading region with the largest 50000 expected
Slide 15: Transformed from agents and distributors to direct sales
Successfully transformed from sales via agents & distributors to direct sales to customer
Slide 16: New sales volume from 3 main pillars
New sales volume from 3 main pilars 1. 2. 3. Existing customers “Switch market” New R&D pipeline market • Grow with existing • Recruit new generic high- • Early introduction as primary customer demands volume customers to fill API source in new customer available capacity and R&D pipeline products •
Slide 17: Slide 17
Slide 18: The Fikkjebakke plant; Operations and strategy
The Fikkjebakke plant; Operations and strategy
Slide 19: Continued increase in production volume
Continued increase in production volum Capacity development 2010-2025 (MT) 8000 2010-2016, installed capacity @3000MT ~7000 • Full utilisation of capacity in 2015 7000 ~6500 • Development of Creep 1 project during 2016 6000 5000 2017-2018, Creep 1 project 4000 • Process stabilisation and Debottlenec
Slide 20: Continued increase in production volume
Continued increase in production volum Capacity development 2010-2025 (MT) 8000 2022, MEP installation, Q1&Q2 ~7000 • Utilisation of new line excl. solvent 7000 ~6500 recovery part 6000 5000 2023, Ramp up solvent recovery 4000 • New equipment and debottlenecking 4000 3400 3800 3000 3000 2024-2025, F
Slide 21: Production facility, beyond state of the art
Production facility, -”beyond” state of the art Competitive edge by: • Fully automated process. Cost effective, accuracy in operations • Use of non-hazardous solvents. Butanol, not Xylene/Tolouen, etc • One step synthesis. Cost effective, low loss – high yield • Inhouse designed filtering unit. Part
Slide 22: Focus on reducing local and global emissions
Vistin has high focus on reducing local and global emissions, and programs are in place to consume responsibly and recycle where possible
Slide 23: Slide 23
Slide 24: Sustainable Operations, HSE and ESG
Production facility, -”beyond” state of the art Sustainable Operations, HSE and ESG • Zero impact on surrounding environment and safe workplace • Double production volume without increased impact on environment • Invested more than EUR 4 mill in sustainable initiatives, 2020-2023 • Reduced emissions
Slide 25: Vistin Pharma
— Vistin Pharma